Completed
PHASE1
INTERVENTIONAL
NCT00490737
Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is to examine the safety of daptomycin in patients with End Stage Renal Disease.
Detailed Description
This is an open label, non-randomized, non-comparative Phase 1 study designed to evaluate the PK profile, safety and tolerability of intravenous ( i.v.) daptomycin. Non-infected subjects with end stage renal disease undergoing hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD) will be enrolled in this in-patient study.
Interventions
Name:
daptomycin
Type:
DRUG
Description:
6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
Primary Outcomes
Measure:
Pharmacokinetics
TimeFrame:
Study Day 1, 3, 5 and 7 or 8
Description:
Trial Information
NCT ID
NCT00490737
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last Updated
December 15, 2025